Ubiquitin specific peptidase 19 (USP19) is a tumor suppressor in ccRCC and demonstrated that USP19 is a potential prognostic biomarker that could be applied in ccRCC therapy.

Introduction

Renal cell carcinoma (RCC) is one of the most prevalent malignancies of the urinary system, accounting for 2.2% of all adult malignancies globally, with estimations of 403,262 new cases and 175,098 deaths worldwide in 2018 (1). Clear cell (cc)RCC represents the predominant histologic subtype of RCC and constitutes ~70% of all cases (2). The remaining 30% of RCC subtypes, such as chromophobe and papillary RCC, are generally indolent (3). Surgery is the most effective treatment for ccRCC, as chemotherapy and radiotherapy are not as successful in controlling its progression; however, ~25% of clinical patients with ccRCC will develop metastatic disease despite curative surgical removal of the primary tumor (4). The overall 5-year survival rate of RCC patient is 5 -10%, with a median survival of only ~13 months (5). Therefore, the molecular mechanisms underlying ccRCC initiation and progression require improved understanding, which may contribute to the development of novel strategies for treating ccRCC.

Ubiquitin and ubiquitin-like modifications participate in most cellular signaling pathways (6). Ubiquitination is reversed by deubiquitinating enzymes (DUBs) that cleave ubiquitin from the substrate protein (7). There are ~98 DUBs known to be encoded by the human genome, which are grouped into six subfamilies, the largest one being the ubiquitin specific peptidase (USP) family (8). The USP family exhibits a conserved three-domain architecture, comprising the palm, thumb and fingers of a right hand (9). USP19 belongs to the USP family and similar studies have reported that USP19 exhibits diverse roles in biological processes. For example, USP19 is involved in the endoplasmic reticulum-associated degradation pathway and the unfolded protein response (10). Additionally, USP19 has also been identified as a positive regulator involved in regulating autophagy and innate immune responses (11). Furthermore, USP19 also reported to have involved in the pathogenesis of certain cancers. For example, Ewing
sarcoma breakpoint region 1-Friend leukemia integration 1 (EWS-FLI1) is a chimeric oncoprotein uniquely expressed in tumor cells, and constant EWS-FLI1 protein turnover is regulated by the ubiquitin proteasome system (12). USP19 as a specific modulator of EWS-FLI1 protein stability, which mediates an increase in fusion protein deubiquitination by binding to its N-terminal domain to regulate Ewing sarcoma growth (12). In addition, BRCA1-associated protein 1 (BAP1) is a tumor suppressor gene important to the development and prognosis of numerous cancers (13); Shahriyari et al (13) found that USP19 was highly positively associated with BAP1 expression in breast and uveal melanoma. At present, there is limited knowledge regarding the role and impact of USP19 in other cancers, including ccRCC.

In the present study, the expression and clinical significance of USP19 were explored in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) ccRCC samples, and the biological functions of USP19 in ccRCC were investigated in vitro and in vivo.

Materials and methods

Date sources. Level 3 mRNA sequencing (seq) data (downloaded in November 2016) of ccRCC, also known as kidney renal clear cell carcinoma (KIRC), including 539 tumor samples and 72 adjacent normal samples, were downloaded from TCGA database (KIRC RNA-seq; http://www.cbioportal.org/). Clinical information, including age, sex, histological grade, tumor stage, survival time and outcome, were also extracted from TCGA. The copy numbers of 587 ccRCC tissues and 901 paired normal kidney tissues from the TCGA database (KIRC CNV) were obtained. GSE76207 (14) and GSE102101 (15) were obtained from the GEO database (http://www.ncbi.nlm.nih.gov/geo/), and respectively contained 16 and 10 paired tumor and normal kidney tissues.

Bioinformatics analysis of the USP19 transcriptional levels in ccRCC. The KIRC RNA-seq level 3 count data and GSE76207 data were normalized with the negative binomial distribution methodology by R (version 3.4.1) (16) package DESeq2 (17). The GSE102101 sequence reads were mapped to the human genome (hg38) using HISAT2 (version 2.1.0; http://ccb.jhu.edu/software/hisat2/) and transcripts were quantified using gene expression in breast and uveal melanoma. At present, there is limited knowledge regarding the role and impact of USP19 in other cancers, including ccRCC.

In the present study, the expression and clinical significance of USP19 were explored in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) ccRCC samples, and the biological functions of USP19 in ccRCC were investigated in vitro and in vivo.

Materials and methods

Date sources. Level 3 mRNA sequencing (seq) data (downloaded in November 2016) of ccRCC, also known as kidney renal clear cell carcinoma (KIRC), including 539 tumor samples and 72 adjacent normal samples, were downloaded from TCGA database (KIRC RNA-seq; http://www.cbioportal.org/). Clinical information, including age, sex, histological grade, tumor stage, survival time and outcome, were also extracted from TCGA. The copy numbers of 587 ccRCC tissues and 901 paired normal kidney tissues from the TCGA database (KIRC CNV) were obtained. GSE76207 (14) and GSE102101 (15) were obtained from the GEO database (http://www.ncbi.nlm.nih.gov/geo/), and respectively contained 16 and 10 paired tumor and normal kidney tissues.

Bioinformatics analysis of the USP19 transcriptional levels in ccRCC. The KIRC RNA-seq level 3 count data and GSE76207 data were normalized with the negative binomial distribution methodology by R (version 3.4.1) (16) package DESeq2 (17). The GSE102101 sequence reads were mapped to the human genome (hg38) using HISAT2 (version 2.1.0; http://ccb.jhu.edu/software/hisat2/) and transcripts were quantified using stringtie (version 1.3.4; http://ccb.jhu.edu/software/stringtie/) with refseq annotation, normalized and subjected to differential expression analysis using DESeq2.

Copy number variation analysis. The KIRC copy-number variation (CNV) data were annotated by bedtools (https://bedtools.readthedocs.io/).

Subgroup analysis based on clinicopathologic features. To further explore the role of USP19, KIRC tumor samples were divided into various groups based on their clinicopathological features (age, sex, histological grade and stage). Then, differential expression analysis of the tumor samples in each group was conducted by t-test.

Survival analysis. Gene Expression Profiling Interactive Analysis (http://gepia.cancer-pku.cn/) was used to analyze the overall survival (OS) and disease-free survival (DFS) differences between patients with high or low expression levels of USP19. Patients above the upper quartile with respect to USP19 expression were classified as having a high expression level, whereas those below the lower quartile were classified as having a low expression level. Those patients with USP19 expression values between the lower and upper quartiles were excluded from survival analysis. Kaplan-Meier analysis and a log-rank test was used to calculate the significance of survival time differences between the two classes of patients.

Plasmid construction and transfection. Full-length human USP19 mRNA was cloned from a human cDNA library and inserted into the mammalian expression vector pHAGE-3xflag (Invitrogen; Thermo Fisher Scientific, Inc.) to construct a pHAGE-3xflag-USP19 plasmid. Two short hairpin RNAs (shRNAs) targeting different regions of USP19 mRNA (shUSP19#1 and shUSP19#2) were inserted into the plKO.1 vector (OligoEngine) and confirmed by sequencing. The sequences of the shRNAs were 5’-CTCCTACTGCGAGCCA AGTATT-3’ (shUSP19#1), 5’-CCGGTACTCTTGAGTGTG ATT-3’ (shUSP19#2) and 5’-GUCAGGGCGAGAAGUU UU-3’ [control shRNA (shctrl)]. Lentiviral supernatants were harvested 48 h after 293T cells at 80-90% confluency were co-transfected with packaging plasmid (0.5 µg pMD2.G and 0.75 µg psPAX2; Novagen; Merck KGaA) and 1 µg pHAGE-3xflag-USP19, empty pHAGE-3xflag, shUSP19#1, shUSP19#2 or shctrl plasmid using polyetherimide transfection reagent (cat. no. GF95797287; Sigma-Aldrich; Merck KGaA). The lentivirus was harvested 48 h after transfection, and Caki-1 cells (5x10^5 cells/well) were incubated with lentivirus-containing medium (MOI=50) supplemented with 2 µl polybrene (Sigma-Aldrich; Merck KGaA). At 48 h later, stable Caki-1 cells were selected in the presence of 4 µg/ml puromycin (Sigma-Aldrich; Merck KGaA) for 2 days. USP19 mRNA expression was examined by reverse transcription-quantitative PCR (RT-qPCR) and protein expression was evaluated using western blotting.

Cell lines and reagents. 293T cells were obtained from American Type Culture Collection. The human renal cancer cell line Caki-1 was purchased from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences. 293T and Caki-1 cells were cultured in DMEM (cat. no. C11995500BT; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (cat. no. F04-001; Biological Industries) and 1% penicillin/streptomycin (cat. no. 15140-122; Gibco; Thermo Fisher Scientific, Inc.), and the cells were cultured in a humidified atmosphere containing 5% CO_2 at 37°C. U0126 (cat. no. HY-12031; MedChemExpress LLC), an ERK inhibitor, was dissolved in DMSO and used to treat Caki-1 cells at a concentration of 20 µm.

Cell proliferation. Cell Counting Kit-8 (CCK-8) assays were performed to evaluate the proliferation capacity of Caki-1 cells. Cells were seeded into 96-well plates at a density of 3x10^3/well. After incubation for various timepoints (0, 24, 48, 72 and 96 h), 10 µl CCK-8 reagent (Dojindo Molecular Technologies, Inc.) was added to each well, followed by incubation for a further 4 h at room temperature. Then, the cell proliferation ability
was examined by measuring the absorbance at 450 nm using an enzyme label analyzer.

For soft agar assays, 3,000 cells were seeded onto 6-well plates containing 0.5% top agarose and 1% bottom agarose, and incubated for 2 weeks in a humidified atmosphere containing 5% CO\textsubscript{2} at 37\degree C. The number of colonies in each plate was counted using Image J software version 1.47 (National Institutes of Health).

Transwell migration assay. Migration assays were performed using 5-mm Transwell\textsuperscript{®} inserts with 5-µm pore polycarbonate membranes (Corning, Inc.). A 0.5-ml cell suspension (2.5x10\textsuperscript{4} cells) in serum-free culture medium was added to the upper chambers, and 750 µl culture medium containing 10% FBS was added to the lower chambers. After 24 h, the cells on the upper surface of the membrane were quickly wiped away with cotton-tipped swabs, and the cells on the lower surface were fixed with 4% paraformaldehyde for 15 min at room temperature, following by staining with a 0.1% crystal violet solution (Sigma-Aldrich; Merck KGaA) for 30 min at room temperature. Cell counting was performed by photographing the membrane through a light microscope. Four random microscopic fields (magnification, x100) in each chamber were photographed.

Wound healing assay. Cells were seeded at 5x10\textsuperscript{5} cells/well into 6-well plates. After the cells reached ~90% confluence, three separate wounds were scratched through the cells with a sterile 100-µl pipette tip. Floating cells were removed with PBS and the medium was replaced with serum-free medium. Images were captured at 0 and 48 h following the initial scratch to evaluate cell migration. Cell migration rate (%)=[(scratch width at 0 h-scratch width at 48 h)/original scratch width x 100%].

RNA extraction and RT-qPCR. Total RNA from cells were extracted using TRIzol\textsuperscript{®} reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocols. For qPCR assays, total RNA was reverse transcribed into cDNA using a Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics) according to the manufacturer's protocols. The expression of USP19 was measured by qPCR using SYBR Green PCR Master Mix (Roche Diagnostics). qPCR was performed as follows: Initial denaturation for 2 min at 55\degree C and 30 sec at 95\degree C, followed by 35 cycles of 95\degree C for 5 sec and 60\degree C for 30 sec. 18S ribosomal RNA was used as an internal control, and the relative mRNA expression was estimated using the $2^{\Delta\Delta Cq}$ method (18). The primer sequences are shown in Table I.

Protein extraction and western blot assay. Total protein was extracted using RIPA lysis buffer (50 mM Tris- HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS and 1 mM EDTA) containing a protease inhibitor cocktail (cat. no. 4963124001; Roche Diagnostics). The protein concentrations were quantified using a bicinchoninic acid assay kit, and 30-50 µg protein was boiled for 5 min and used for western blot analysis. The proteins were separated by 8-12% SDS-PAGE and transferred to PVDF membranes at 200 mA for 1 h. The PVDF membranes were blocked with 5% nonfat milk at room temperature for 1 h. Next, the membranes were incubated with primary antibodies (1:1,000) at 4\degree C overnight and washed with TBS-0.1% Tween-20 three times. The membranes were further incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:10,000; cat. nos. 111-035-003 and 115-035-003; Jackson ImmunoResearch Laboratories, Inc.) at 37\degree C for 1 h. Finally, the membranes were developed by Femto ECL substrates (Thermo Fisher Scientific, Inc.) and captured by a Chemi HR camera. The images were analyzed by Image Lab 19.

| Gene   | Primer                                                                 |
|--------|------------------------------------------------------------------------|
| p27    | F: 5'-GGTGGAGAAGGGCAGTTG-3'                                            |
|        | R: 5'-GAAGAATCTGCGTGTGGAG-3'                                           |
| PCNA   | F: 5'-CAGATCATCGCAACACCCG-3'                                           |
|        | R: 5'-AGGGCGTATGAGACGAAAGGA-3'                                         |
| Cyclin D1 | F: 5'-CCGTCGCCCATCACTCAGTT-3'                                         |
|        | R: 5'-CCGATCGGTCTCGATGAT-3'                                            |
| MMP2   | F: 5'-TTTGGATCCGGGATCGAGTG-3'                                          |
|        | R: 5'-TTTGTCGCGGATAGAAAGGGG-3'                                         |
| MMP9   | F: 5'-TTGAGTCCGGGAGCGATCGGAGG-3'                                       |
|        | R: 5'-TTGTCGCGGATAAGGAAGGGG-3'                                         |
| USP19  | F: 5'-TAAATCCAAGGCCACAGTCTGAGG-3'                                      |
|        | R: 5'-GCCTTTGGGGTACATGCTTCA-3'                                         |
| 18S rRNA | F: 5'-GTAACCGGTGACCACCCCATT-3'                                         |
|        | R: 5'-CCATCCAATCGTAGTACGGG-3'                                          |

Table II. Relationship between the expression of USP19 and clinicopathological characteristics.

| Characteristic   | Cases, n | USP19 mean expression value | P-value |
|-----------------|----------|-----------------------------|---------|
| Age ≤60         | 249      | 2,749.977±913.719           | 0.2254  |
| >60             | 289      | 2,661.380±755.453           |         |
| Sex Male        | 353      | 2,658.620±827.082           | 0.0933  |
|                 | Female   | 186                         |         |
| Histological grade Low | 249     | 2,775.497±890.832           | 0.0086  |
|                 | High     | 252                         |         |
| Stage I-II      | 331      | 2,832.380±961.756           | <0.0001 |
|                 | III-IV   | 205                         |         |

PCNA, proliferating cell nuclear antigen; MMP, matrix metalloproteinase; USP19, ubiquitin specific peptidase 19; rRNA, ribosomal RNA.

| Table I. Primer sequences.                                                                 |
|---------------------------------------------------------------------------------------------|
| Gene   | Primer                                                                 |
|--------|------------------------------------------------------------------------|
| p27    | F: 5'-GGTGGAGAAGGGCAGTTG-3'                                            |
|        | R: 5'-GAAGAATCTGCGTGTGGAG-3'                                           |
| PCNA   | F: 5'-CAGATCATCGCAACACCCG-3'                                           |
|        | R: 5'-AGGGCGTATGAGACGAAAGGA-3'                                         |
| Cyclin D1 | F: 5'-CCGTCGCCCATCACTCAGTT-3'                                         |
|        | R: 5'-CCGATCGGTCTCGATGAT-3'                                            |
| MMP2   | F: 5'-TTTGGATCCGGGATCGAGTG-3'                                          |
|        | R: 5'-TTGTCGCGGATAAGGAAGGGG-3'                                         |
| MMP9   | F: 5'-TTGAGTCCGGGAGCGATCGGAGG-3'                                       |
|        | R: 5'-TTGTCGCGGATAAGGAAGGGG-3'                                         |
| USP19  | F: 5'-TAAATCCAAGGCCACAGTCTGAGG-3'                                      |
|        | R: 5'-GCCTTTGGGGTACATGCTTCA-3'                                         |
| 18S rRNA | F: 5'-GTAACCGGTGACCACCCCATT-3'                                         |
|        | R: 5'-CCATCCAATCGTAGTACGGG-3'                                          |

PCNA, proliferating cell nuclear antigen; MMP, matrix metalloproteinase; USP19, ubiquitin specific peptidase 19; rRNA, ribosomal RNA.
HY et al: USP19 AFFECTS THE PROLIFERATION AND MIGRATION OF CCRCC

3.1 software (Bio-Rad Laboratories, Inc.). Primary antibodies targeting USP19 (cat. no. ab93159; Abcam), p27 (cat. no. 3688; Cell Signaling Technology, Inc.), proliferating cell nuclear antigen (PCNA; cat. no. 2586; Cell Signaling Technology, Inc.), cyclin D1 (cat. no. 2922; Cell Signaling Technology, Inc.), matrix metalloproteinase (MMP)2 (cat. no. A11144; ABclonal Biotech Co., Ltd.), MMP9 (cat. no. A0289; ABclonal Biotech Co., Ltd.), phosphorylated (p)-ERK (cat. no. 4370; Cell Signaling Technology, Inc.), ERK (cat. no. 4695; Cell Signaling Technology, Inc.), β-actin (cat. no. 4967; Cell Signaling Technology, Inc.) were used.

Xenograft model. All animal protocols conducted in the present study were approved by the Institutional Animal Care and Use Committee of the Institute of Model Animals of Wuhan University. All animal care outlined in our study were performed in adherence with the Guide for the Care and Use of Laboratory Animals published by US National Institutes of Health (19). The following criteria were set as humane endpoints for the study: Abnormal behavior; ±20% change in body weight; tumor diameter >1.5 cm; or tumor ulceration. The maximum tumor diameter was not exceeded until day 60 of the study, when animals were sacrificed; the maximum diameter observed in any one direction was 1.95 cm.

A total of 10 BALB/c female mice (4–6 weeks; 17–18 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed under specific pathogen-free conditions and a 12-h light/dark cycle, at 25°C with 60±10% humidity, and free access to food and water. A total of 5x10⁶ stably infected cells were diluted in 150 µl DMEM and Matrigel, and inoculated subcutaneously into the left flank of each mouse (5 mice/group). The tumor volumes (V) were measured every 5 days, and calculated using the following formula: V=0.5x(length x width²). At 60 days after injection, mice were sacrificed via cervical dislocation. If no spontaneous breathing was observed for 3 min and the blink reflex was lost, mice were considered to be euthanized. During the study, no animals were prematurely euthanized or found dead. The tumors were removed from the mice, weighed and used for western blot assays.

Statistical analysis. The data were presented as the mean ± SD of ≥3 experimental repeats using GraphPad Prism 5 software (GraphPad Software, Inc.). Comparisons between two groups were performed using two-tailed Student’s t-tests. Differences among 3 groups were assessed using one-way ANOVA followed by Bonferroni test (equal variances assumed) or Tamhane’s T2 test (equal variances not assumed). Differences among 4 groups were assessed using two-way ANOVA followed by Bonferroni test. Statistical analyses were performed using SPSS 19 Statistics software (IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

Results

USP19 is downregulated due to copy number loss in ccRCC tissues. To explore whether USP19 was involved in the pathogenesis of ccRCC, its expression was first detected in patients with ccRCC and healthy controls. RNA-seq data from the samples of 539 patients with ccRCC from TCGA database
Figure 2. Low USP19 expression is associated with clear cell renal cell carcinoma prognosis. Gene Expression Profiling Interactive Analysis revealed associations between USP19 expression and (A) OS and (B) DFS rates according to The Cancer Genome Atlas kidney renal clear cell carcinoma data. OS, overall survival; DFS, disease-free survival; USP, ubiquitin specific peptidase; TPM, transcript per million.

Figure 3. USP19 overexpression inhibits clear cell renal cell carcinoma cell proliferation in vitro. Expression of USP19 was evaluated by (A) RT-qPCR and (B) western blotting in USP19-overexpressing or control Caki-1 cells. (C) Cell Counting Kit-8 assays and (D) and soft agar assays were performed to detect cell proliferation in USP19-overexpressing or control Caki-1 cells. (E) RT-qPCR analysis of PCNA, cyclin D1 and p27 mRNA levels in USP19-overexpressing or control Caki-1 cells. (F) Western blot analysis of PCNA, cyclin D1 and p27 protein levels in USP19-overexpressing or control Caki-1 cells. β-actin was used as the loading control, and 3 replicates of the indicated proteins were quantified by Image Lab software. Data are presented as the mean ± SD of three independent experiments. *P<0.05, **P<0.01 vs. ctrl. USP, ubiquitin specific peptidase; RT-qPCR, reverse transcription-quantitative PCR; PCNA, proliferating cell nuclear antigen; OD, optical density.
HU et al: USP19 AFFECTS THE PROLIFERATION AND MIGRATION OF CCRCC

and 26 patients with ccRCC from GEO (GSE76207 and GSE102101) were employed. The results indicated that USP19 expression was significantly reduced in renal cancer tissues compared with normal renal tissues (P<0.0001; Fig. 1A-C). DNA CNVs are common in cancer and are responsible for the dysregulation of gene expression (20). To explain the mechanism of USP19 downregulation in ccRCC, the CNVs of the USP19 gene in 901 normal kidney tissue samples and 587 KIRC samples from TCGA were assessed. The results demonstrated that the USP19 gene copy number was significantly lower in ccRCC tissues than in normal tissues (P=2.2x10^{-16}; Fig. 1D). These results indicated that USP19 expression is significantly decreased in ccRCC tissues, which may be due to copy number loss.

USP19 downregulation is associated with high tumor stage and poor prognosis. The associations between USP19 expression and clinicopathological features were further evaluated in TCGA KIRC cohort. Data showed that USP19 expression levels were significantly reduced in patients at a more advanced clinical stage (P<0.0001) and higher histological grade, (P=0.0086), but was not significant different between patients separated by age (P=0.2254) or sex (P=0.0933; Table II).

Survival analysis revealed that patients with ccRCC with low USP19 expression exhibited significantly worse OS and DFS compared with those with high USP19 expression (P<0.05; Fig. 2A and B). In conclusion, these results suggested that USP19 downregulation is associated with high tumor stage and poor prognosis.

Overexpression of USP19 inhibits ccRCC cell proliferation in vitro. To explore the potential biological functions of USP19 in ccRCC, USP19-overexpressing cells were constructed by lentiviral infection of Caki-1 cells in vitro. USP19 mRNA and protein levels were significantly increased in USP19-overexpressing cells (P<0.05; Fig. 3A and B). Caki-1 cell proliferation was assessed via CCK-8 assays, and the results showed that proliferation was significantly
Figure 5. USP19 inhibits clear cell renal cell carcinoma cell migration in vitro. Migration abilities of (A) USP19-overexpressing and (B) knockdown Caki-1 cells were determined via Transwell assays; scale bar=100 µm, n=4. Migration abilities of (C) USP19-overexpressing and (D) knockdown Caki-1 cells were determined via wound healing assays; scale bar=300 µm, n=4. Reverse transcription-quantitative PCR analysis of MMP2 and MMP9 mRNA levels in (E) USP19-overexpressing or (F) knockdown Caki-1 cells; n=3. Protein expression of MMP2 and MMP9 in (G) USP19-overexpressing or (H) knockdown Caki-1 cells; n=3. Data are presented as the mean ± SD. *P<0.05, **P<0.01. USP, ubiquitin specific peptidase; RT-qPCR, reverse transcription-quantitative PCR; MMP, matrix metalloproteinase; sh, short hairpin RNA.
Hu et al: USP19 AFFECTS THE PROLIFERATION AND MIGRATION OF CCRCC

Reduced in USP19-overexpressing Caki-1 cells compared with in control cells (all P<0.05; Fig. 3C). Furthermore, soft agar assays showed that the colony number was significantly decreased for USP19-overexpressing Caki-1 cells compared with control cells (P<0.01; Fig. 3D). Previous reports indicated that cyclin D1 and PCNA are involved in cell cycle control (21) and that p27 is a cyclin-dependent kinase inhibitor (22); these genes are thus markers of cell proliferation. Thus, mRNA levels of PCNA, cyclin D1, and p27 were evaluated via RT-qPCR. The results showed that mRNA levels of PCNA and cyclin D1 were downregulated when USP19 was overexpressed, whereas p27 was upregulated (all P<0.05; Fig. 3E). Consistently, the protein levels of PCNA and cyclin D1 were decreased, and those of p27 were increased in USP19-overexpressing cells compared with control cells (all P<0.05; Fig. 3F). Taken together, the above results indicated that USP19 inhibits ccRCC cell proliferation.

Knockdown of USP19 expression promotes ccRCC cells proliferation in vitro. To examine whether USP19 knockdown promotes ccRCC cell proliferation, lentivirus-mediated shRNA constructs targeting different USP19 mRNA regions were applied to generate two stable USP19 knockdown cell lines. USP19 mRNA and protein levels were significantly reduced in stable USP19 knockdown Caki-1 cells compared with in shctrl Caki-1 cells (all P<0.05; Fig. 4A and B). CCK-8 and soft agar assays also showed that Caki-1 cell proliferation was increased following USP19 knockdown (all P<0.05; Fig. 4C and D). Accordingly, the mRNA levels of PCNA and cyclin D1 were higher, and those of p27 were lower in the USP19 knockdown group compared with in the shctrl group (all P<0.05; Fig. 4E). Similarly, the protein levels of PCNA and cyclin D1 were increased, while those of p27 were decreased by USP19 knockdown (all P<0.05; Fig. 4F).
These results indicated that USP19 knockdown promotes ccRCC cell proliferation.

**USP19 inhibits ccRCC cell migration in vitro.** Having observed a significant change in cell proliferation following the dysregulation of USP19 expression, the effects of USP19 on cell migration were further evaluated using Transwell and wound healing assays. Transwell assays showed that cell migration was impaired in USP19-overexpressing Caki-1 cells, whereas it was promoted in USP19 knockdown Caki-1 cells compared with the respective negative controls (all \( P<0.01 \); Fig. 5A and B). Similarly, microscopic examination of wounds at 0 and 48 h showed that the migration rate in the USP19 overexpression group was significantly reduced, whereas it was increased in USP19 knockdown group compared with the control groups (all \( P<0.05 \); Fig. 5C and D). MMP2 and MMP9 are frequently with the malignant phenotype of tumor cells, and are commonly used as malignant tumor migration markers (23,24). RT-qPCR and western blot data showed that the expression levels of MMP2 and MMP9 were lower in USP19-overexpressing cells and higher in USP19-knockdown cells than in control cells (all \( P<0.05 \); Fig. 5E-H). These data indicated that USP19 inhibits ccRCC cell migration in vitro.

**USP19 regulates ccRCC cell proliferation and migration by regulating the ERK signaling pathway.** ERK/mitogen-activated protein kinase (MAPK) signaling has been shown to be involved in various cancer-associated pathological processes (25,26). To investigate the underlying molecular signaling pathways that participate in USP19-mediated inhibition of proliferation and migration in ccRCC cancer cells, ERK activity was determined in USP19-overexpressing and knockdown Caki-1 cells. Of note, it was found that total ERK protein levels were not notably changed in the USP19 knockdown or overexpression ccRCC cells. However, USP19 overexpression clearly reduced p-ERK levels, while USP19 knockdown increased ERK phosphorylation (all \( P<0.01 \); Fig. 6A and B), indicating that ERK may mediate the functions of USP19 in ccRCC cancer cells. Thus, the effects of the ERK inhibitor U0126 on the functions of USP19 in ccRCC cancer cells were determined. As the CCK-8 assay showed, U0126 significantly rescued the increased Caki-1 cell proliferation induced by USP19 knockdown (all \( P<0.01 \); Fig. 6C). Transwell assays also indicated that the promoting effects of USP19 knockdown on Caki-1 cell migration were reversed by U0126 (all \( P<0.05 \); Fig. 6D). Treatment of U0126 led to a significant decrease in p-ERK levels, whilst not notably affecting the total ERK protein levels (all \( P<0.01 \); Fig. 6E). Hence, these results demonstrated that USP19 regulates ccRCC proliferation and migration through its regulation of ERK signaling.

**USP19 inhibits tumorigenesis in ccRCC cells in vivo.** To investigate the effect of USP19 in vivo, nude mice were inoculated with shctrl- or shUSP19#1-infected Caki-1 cells. Compared with the tumors created by the shctrl cells, the tumors derived from the shUSP19#1-infected Caki-1 cells were significantly larger (all \( P<0.05 \); Fig. 7A and B). Consistently, the tumor weights at 60 days were significantly heavier in the shUSP19#1 group than the shctrl group (all \( P<0.05 \); Fig. 7C), whereas the body weights at 60 days of the mice in the two groups were not significantly different (all \( P>0.05 \); Fig. 7D). Then, western blot experiments revealed notably increased p-ERK levels in the tumor tissues derived from the shUSP19#1 group compared with those derived from the shctrl group (Fig. 7E). These find-
ings indicated that USP19 downregulation promotes ccRCC tumor growth in vivo.

**Discussion**

The present study revealed that USP19 may function as a tumor suppressor in ccRCC, and that USP19 expression is significantly reduced in ccRCC tissues, based on multiple downloaded datasets. Furthermore, the present study also demonstrated that USP19 downregulation in ccRCC was associated with more advanced tumors and predicted unfavorable prognostic outcomes in a TCGA cohort.

CCK-8 assays are conducted to assess cancer cell proliferation abilities, and Transwell and wound healing assays are used to evaluate migration abilities (32-35). To investigate the observations from the bioinformatics analyses, in vitro cell line experiments were conducted, indicated that USP19 overexpression suppressed proliferation and migration, whereas USP19 knockdown promoted proliferation and migration. At the molecular level, USP19 overexpression decreased the expression of the proliferation-promoting genes PCNA and cyclin D1, and increased the expression of the proliferation-inhibiting gene p27; conversely, USP19 overexpression decreased the expression of the migration-associated genes MMP2 and MMP9. Conversely, depletion of USP19 inhibited proliferation in DU145, PC-3 and 22RV1 prostate cancer cells, indicating that USP19 has distinct functions in different tumors (36).

Aberrant ERK-MAPK pathway signaling contributes to cell proliferation and migration in various types of cancer (37,38). In the present study, USP19 overexpression reduced p-ERK levels. Moreover, USP19 knockdown promoted ERK phosphorylation, as well as promoting ccRCC proliferation in vitro and in vivo. Therefore, these results suggested that the molecular mechanism underlying USP19-mediated proliferation and migration inhibition in ccRCC may depend on inactivation of the ERK-MAPK signaling pathway. However, one limitation of the present study is that the colocalization of USP19 and p-ERK was not confirmed in mouse tumor tissues, due to low quantities and poor specificity of the USP19 antibody.

Wu et al (39) previously reported that USP19 expression was lower in ccRCC tissue compared with in normal kidney tissue by analyzing TCGA KIRC data. Liu et al (40) analyzed gene and isoform expression signatures associated with tumor stage in KIRC and found uc003cvz.3, the major isoform of USP19, was significantly downregulated in patients with stage IV KIRC, whereas higher uc003cvz.3 expression suggested improved survival rates. However, these two studies only showed the clinical relationship of USP19 and ccRCC by analyzing databases; they did not investigate the biological functions of USP19 in ccRCC cells. Conversely, the present study demonstrated that USP19 overexpression inhibited ccRCC cell proliferation and migration in vitro; conversely, USP19 knockdown promoted proliferation and migration in vitro, as well as promoting tumor growth in vivo. To the best of our knowledge, this is the first study to investigate the biological functions and molecular mechanisms of USP19 in ccRCC. These findings expand current knowledge regarding USP19, and suggest that USP19 may play an important role in the development and progression of ccRCC.

**Acknowledgments**

Not applicable.

**Funding**

This work was supported by Hubei Health Research Foundation (grant no. WJ2019F039).

**Availability of data and materials**

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

**Authors’ contributions**

ZT and JZ designed the study. WH, YS, XF, XW and GZ performed the experiments. WH, YS, CS, TD, TY and GW performed data analysis. WH, YS, ZT and JZ contributed to manuscript revisions and all the authors reviewed the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

All protocols involving animals were approved by the Institutional Animal Care and Use Committee of the Institute of Model Animals of Wuhan University.

**Patient consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
2. Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet 373: 1119-1132, 2009.
3. Delahant B, Bethwaite PB and Nacey JN: Outcome prediction for renal cell carcinoma: Evaluation of prognostic factors for tumors divided according to histological subtype. Pathology 39: 459-465, 2007.
4. Lin YF, Chou JL, Chang JS, Chiu JJ, Chiu HW and Lin YF: Dysregulation of the miR-25-IMPA2 axis promotes metastatic progression in clear cell renal cell carcinoma. EBioMedicine 45: 220-230, 2019.
5. Afriansyah A, Hamid AR, Mochtar CA and Umbas R: Targeted therapy for metastatic renal cell carcinoma. Acta Med Indones 48: 335-347, 2016.

6. Bae YK and Dikic I: Ubiquitin-binding proteins: Decoders of ubiquitin-mediated cellular functions. Annu Rev Biochem 81: 291-322, 2012.

7. Harada K, Kato M and Nakamura N: USP19-mediated deubiquitination facilitates the stabilization of HRDI ubiquitin ligase. Int J Mol Sci 17: pii: E1829, 2016.

8. Fraile JM, Quesada V, Rodriguez D, Freije JM and López-Otín C: Deubiquitinases in cancer: New functions and therapeutic options. Oncogene 31: 2373-2388, 2012.

9. Jin S, Tian S, Chen Y, Han L, Li P, Li M, Yao T, Wu JW, Gu W, Cohen RE and Shi Y: Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111: 1041-1054, 2002.

10. Hassink GC, Zhao B, Sompallae R, Altun M, Gastaldello S, Zinin NV, Masucci MG and Lindsten K: The ER-resident ubiquitin-specific protease 19 participates in the UPR and rescues ERAD substrates. EMBO Rep 10: 755-761, 2009.

11. Jin S, Tian S, Chen Y, Zhang C, Xie W, Xue X, Cui J and Wang RF: USP19 modulates autophagy and antiviral immune responses by deubiquitinating Beclin-1. EMBO J 35: 866-880, 2016.

12. Gierisch ME, Pedot G, Walse M, Lopez-Garcia LA, Jaaks P, Niigli FK and Schäfer BW: USP19 deubiquitinates EWS-F11 to regulate Ewing sarcoma growth. Cell Rep 9: 951, 2019.

13. Shahriyari L, Abdel-Rahman M and Cebulla C: BAP1 expression is prognostic in breast and uveal melanoma but not colon cancer and is highly positively correlated with RBBM15B and USP19. PLoS One 14: e0211507, 2019.

14. Eikrem O, Beisland C, Hjelle K, Flatberg A, Scherer A, Landolt L, Eikeland J, Sixta M, Linfert K, Velasco A, et al: Deubiquitination regulates MYC reveals common enhancer-docking mechanism. Cell 111: 1041-1054, 2002.

15. Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15: 550, 2014.

16. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression through the ERK/MAPK signaling pathway. Oncol Lett 16: 6051-6058, 2018.

17. Lu Y, Bedard N, Chevalier V and Wing SS: Identification of distinctive patterns of USP19-mediated growth regulation in normal and malignant cells. PLoS One 6: e15936, 2011.

18. Li B, Liu Y, Sun AG, Huang LC, Li HD and Liu DM: MiR-130b promotes non-small lung cancer cell proliferation and metastasis by regulating LZTS3 expression. Ann Oncol 29: 2680-2687, 2018.

19. Shi Y, Zhang C, Xie W, Xia X, Cui J and Wang RF: Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111: 1041-1054, 2002.

20. Björklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755: 37-69, 2005.

21. O’Connor MJ, Carter P and Crolla JA: MiR-210 and cancer. Oncologist 14: 1723-1734, 2009.

22. Eikrem O, Beisland C, Hjelle K, Flatberg A, Scherer A, Landolt L, Eikeland J, Sixta M, Linfert K, Velasco A, et al: Deubiquitination regulates MYC reveals common enhancer-docking mechanism. Cell 111: 1041-1054, 2002.

23. Wang Y, Zhang C, Xie W, Xia X, Cui J and Wang RF: Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111: 1041-1054, 2002.

24. Mu R and Zhang WN: USP19 deubiquitates HDAC1/2 to enhance cell viability, proliferation and cell apoptosis in HepG2. Cancer Med 7: 6182-6192, 2018.

25. Wang Y, Zheng C, Li T, Zhang R, Wang Y, Zhang J, He Q, Sun Z and Wang X: Long non-coding RNA Z38 promotes cell proliferation and metastasis and inhibits cell apoptosis in human gastric cancer. Oncol Lett 16: 6051-6058, 2018.

26. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

27. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

28. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

29. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

30. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

31. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

32. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

33. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

34. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

35. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

36. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

37. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

38. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.

39. Wang L, Zhao H, Xu Y, Li J, Deng C, Deng Y, Bai J, Li X, Xiao Y and Zhang Y: Systematic identification of lincRNA-based prognostic biomarkers by integrating lincRNA expression and copy number variation in lung adenocarcinoma. Int J Cancer 144: 1723-1734, 2019.